An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19.
作者信息
Homolak Jan, Kodvanj Ivan, Trkulja Vladimir
机构信息
Department of Pharmacology, University of Zagreb School of Medicine, 10 000, Zagreb, Croatia.
出版信息
Clin Drug Investig. 2021 Mar;41(3):287-289. doi: 10.1007/s40261-021-01007-8. Epub 2021 Feb 19.
Abstract
摘要
相似文献
1
An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19.关于质子泵抑制剂作为2019冠状病毒病风险因素的另一种观点
Clin Drug Investig. 2021 Mar;41(3):287-289. doi: 10.1007/s40261-021-01007-8. Epub 2021 Feb 19.
2
Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?质子泵抑制剂是病毒感染的风险因素：对新冠病毒感染而言也是如此吗？
Clin Drug Investig. 2020 Oct;40(10):897-899. doi: 10.1007/s40261-020-00963-x.
3
COVID-19 Mortality: The Culprit May Not Be Proton Pump Inhibitors.新冠病毒肺炎死亡率：罪魁祸首可能并非质子泵抑制剂。
Clin Gastroenterol Hepatol. 2022 Jan;20(1):247-248. doi: 10.1016/j.cgh.2021.08.013. Epub 2021 Aug 12.
4
Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis.质子泵抑制剂的使用与新型冠状病毒肺炎不良临床结局风险：一项荟萃分析
J Intern Med. 2021 Jan;289(1):125-128. doi: 10.1111/joim.13183. Epub 2020 Oct 20.
5
Response to "Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy".对“接受质子泵抑制剂治疗的COVID-19患者ACE2水平升高与死亡风险”的回应
Am J Gastroenterol. 2021 Dec 1;116(12):2474. doi: 10.14309/ajg.0000000000001495.
6
Comment on Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors.关于质子泵抑制剂使用者中新冠病毒肺炎（COVID-19）风险增加的评论
Am J Gastroenterol. 2020 Nov;115(11):1921. doi: 10.14309/ajg.0000000000001014.
7
Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort.质子泵抑制剂与重症新型冠状病毒肺炎风险：一项来自韩国全国队列的事后分析
Gut. 2021 Oct;70(10):2013-2015. doi: 10.1136/gutjnl-2020-323672. Epub 2020 Dec 10.
8
Response to Hajifathalian and Katz Regarding Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors.对哈吉法萨利安和卡茨关于质子泵抑制剂使用者中新冠病毒肺炎（COVID-19）风险增加的回应。
Am J Gastroenterol. 2020 Nov;115(11):1922-1923. doi: 10.14309/ajg.0000000000000993.
9
Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?使用质子泵抑制剂治疗会增加新冠肺炎住院患者继发感染和急性呼吸窘迫综合征的风险：是巧合还是被低估的风险因素？
J Intern Med. 2021 Jan;289(1):121-124. doi: 10.1111/joim.13121. Epub 2020 Jul 1.
10
The Proton Pump Inhibitors Use and COVID-19 from Prior to Vaccination Perspective: A Review.质子泵抑制剂的使用与疫苗接种前的 COVID-19 ：综述。
Dig Dis. 2023;41(3):513-521. doi: 10.1159/000527501. Epub 2022 Oct 18.
本文引用的文献
1
Might proton pump or sodium-hydrogen exchanger inhibitors be of value to ameliorate SARs-CoV-2 pathophysiology?质子泵或钠-氢交换器抑制剂是否有助于改善 SARS-CoV-2 病理生理学？
Physiol Rep. 2021 Jan;8(24):e14649. doi: 10.14814/phy2.14649.
2
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study.质子泵抑制剂或法莫替丁的使用与重症 COVID-19 疾病：一项倾向评分匹配的全地区研究。
Gut. 2021 Oct;70(10):2012-2013. doi: 10.1136/gutjnl-2020-323668. Epub 2020 Dec 4.
3
Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19.COVID-19 患者住院前使用质子泵抑制剂与临床结局的关系
Eur J Gastroenterol Hepatol. 2022 Feb 1;34(2):137-141. doi: 10.1097/MEG.0000000000002013.
4
Five rules for evidence communication.证据传播的五条规则。
Nature. 2020 Nov;587(7834):362-364. doi: 10.1038/d41586-020-03189-1.
5
Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis.质子泵抑制剂会影响与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）相关的结果吗？一项荟萃分析。
Gut. 2021 Sep;70(9):1806-1808. doi: 10.1136/gutjnl-2020-323366. Epub 2020 Nov 10.
6
Are Proton Pump Inhibitors Contributing to SARS-COV-2 Infection?质子泵抑制剂会导致新型冠状病毒感染吗？
Am J Gastroenterol. 2020 Nov;115(11):1920-1921. doi: 10.14309/ajg.0000000000000933.
7
Risk of COVID-19 in Patients Taking Proton Pump Inhibitors.服用质子泵抑制剂的患者感染新型冠状病毒肺炎的风险
Am J Gastroenterol. 2020 Nov;115(11):1919-1920. doi: 10.14309/ajg.0000000000000949.
8
Regarding "Increased Risk of COVID-19 in Patients Taking Proton Pump Inhibitors".关于“服用质子泵抑制剂的患者感染新冠病毒的风险增加”。
Am J Gastroenterol. 2020 Nov;115(11):1918-1919. doi: 10.14309/ajg.0000000000000920.
9
Proton Pump Inhibitors and Mortality in Individuals With COVID-19.质子泵抑制剂与新冠肺炎患者的死亡率
Am J Gastroenterol. 2020 Nov;115(11):1918. doi: 10.14309/ajg.0000000000000992.
10
Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection.使用质子泵抑制剂与2019冠状病毒病（COVID-19）感染的严重程度和死亡率增加有关。
Dig Liver Dis. 2020 Dec;52(12):1410-1412. doi: 10.1016/j.dld.2020.10.001. Epub 2020 Oct 6.
Zotero 插件